In this piece, we will look at the stocks that Jim Cramer recently discussed.

The drugmaker will face more in the next few years. However, Amgen should be able to overcome these challenges. The company's ...

Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing ...

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...

The American Diabetes Association Scientific Sessions, held in June, featured cutting-edge science, from new agents to treat ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday. The US ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Now, biopharmaceutical company Amgen has been developing a new weight loss drug called MariTide—and early trials are showing big results.

My bigger concern, we may not see MariTide get FDA approval and make it to the market until late 2027 at best… Amgen’s very confident that their Phase 3 trial will be successful by the time ...